OphthalmoPharma (OPPH) is a pharmaceutical company specializing in the development of ophthalmology treatments. Our product pipeline addresses major unmet medical needs including dry eye syndrome, glaucoma, and age-related macular degeneration (AMD).
company news
--------------------------------------------
September 17th 2009
The Center for Drug Evaluation and Research of the Food and Drug Administration (CDER/FDA) has agreed in principle to accept our proposed product development plan, which entails the use of an abbreviated registration pathway, formally known as a 505(b)(2) New Drug Application (NDA), in order to obtain CDER/FDA approval of OphthalmoPharma’s Latanoprost CD Ophthalmic Solution product. read more
July 3rd 2008
OphthalmoPharma is pleased to announce that Motti Geron has joined the Company as Projects Manager. His outstanding operational experience will be of particular value to the Company. Motti will be in charge of the projects management and coordination with top management and external partners. read more
May 1 st 2008
OphthalmoPharma drug delivery approach is described in the May 1 2008 (Vol. 28, No. 9) edition of GEN, Genetics Engineering and Biotechnology News. read article
beecomb powered by beecom - beecomb the Professional Swiss CMS
